Invest New Drugs
3. Liu S, Tang Y, Yuan X, Yuan D, Liu J, Li B, Li Y (2018) Inhibition
of Rb and mTOR signaling associates with synergistic anticancer
effect of palbociclib and erlotinib in glioblastoma cells. Investig
4. Alex T, Atique A, Kyung-Sub M, Lesniak MS (2013) The art of
gene therapy for glioma: a review of the challenging road to the
bedside. J Neurol Neurosurg Psychiatry 84(4):326–326
18. Sun H, Luo G, Chen D, Xiang Z (2016) A Comprehensive and
System Review for the Pharmacological Mechanism of Action of
Rhein, an Active Anthraquinone Ingredient. Front Pharmacol 7:
19. Li QH, Wen J, Yu KT, Shu Y, He WL, Chu HX, Zhang B, Ge C
(2018) Aloe-emodin induces apoptosis in human oral squamous
cell carcinoma SCC15 cells. BMC Complement Altern Med 18.
20. Castel P, Scaltriti M (2017) The emerging role of serum/
glucocorticoid-regulated kinases in cancer. Cell Cycle 16(1):5–6.
21. Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, Kannan
S, Verma CS, Dickler M, Chandarlapaty S, Brogi E, Alessi DR,
Baselga J, Scaltriti M (2016) PDK1-SGK1 Signaling Sustains
AKT-Independent mTORC1 Activation and Confers Resistance to
5. Kibble M, Saarinen N, Tang J, Wennerberg K, Mäkelä S,
Aittokallio T (2015) Network pharmacology applications to map
the unexplored target space and therapeutic potential of natural
products. Nat Prod Rep 32(8):1249–1266
6. He M, Luo M, Liu Q, Chen J, Li K, Zheng M, Weng Y, Ouyang L,
Liu A (2016) Combination treatment with fasudil and clioquinol
produces synergistic anti-tumor effects in U87 glioblastoma cells
by activating apoptosis and autophagy. J Neuro-Oncol 127:261–
270
22. Talarico C, Dattilo V, D'Antona L, Barone A, Amodio N, Belviso S,
Musumeci F, Abbruzzese C, Bianco C, Trapasso F, Schenone S,
Alcaro S, Ortuso F, Florio T, Paggi MG, Perrotti N, Amato R (2016)
SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy,
modulates the response to oxidative stress and induces cytotoxic
autophagy in human glioblastoma multiforme cells. Oncotarget 7
23. Wang J, Liu S, Yin Y, Li M, Wang B, Yang L, Jiang Y (2015)
FOXO3-mediated up-regulation of Bim contributes to rhein-
induced cancer cell apoptosis. Apoptosis: an International J
24. Wu C, Cao H, Zhou H, Sun L, Xue J, Li J, Bian Y, Sun R, Dong S,
Liu P, Sun M (2017) Research Progress on the Antitumor Effects of
Rhein: Literature Review. Anti-Cancer Agents Medicinal
25. Zheng SH, Huang JL, Chen M, Wang BL, Ou QS, Huang SY
(2018) Diagnostic value of preoperative inflammatory markers in
patients with glioma: a multicenter cohort study. J Neurosurg
26. Yin XF, Zhang Q, Chen ZY, Wang HF, Li X, Wang HX, Li HX,
Kang CM, Chu S, Li KF, Li Y, Qiu YR (2018) NLRP3 in human
glioma is correlated with increased WHO grade, and regulates cel-
lular proliferation, apoptosis and metastasis via epithelial-
mesenchymal transition and the PTEN/AKT signaling pathway.
27. Orlacchio A, Ranieri M, Brave M, Arciuch VA, Forde T, De
Martino D, Anderson KE, Hawkins P, Di Cristofano A (2017)
SGK1 Is a Critical Component of an AKT-Independent Pathway
Essential for PI3K-Mediated Tumor Development and
28. Marampon F, Leoni F, Mancini A, Pietrantoni I, Codenotti S,
Letizia F, Megiorni F, Porro G, Galbiati E, Pozzi P, Mascagni P,
Budillon A, Maggio R, Tombolini V, Fanzani A, Gravina GL,
Festuccia C (2018) Histone deacetylase inhibitor ITF2357
(givinostat) reverts transformed phenotype and counteracts
stemness in in vitro and in vivo models of human glioblastoma. J
7. Falkenberg KJ, Johnstone RW (2014) Histone deacetylases and
their inhibitors in cancer, neurological diseases and immune disor-
ders. Nat Rev Drug Discov 13(9):673–691
8. Shi XY, Ding W, Li TQ, Zhang YX, Zhao SC (2017) Histone
Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid
(SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the
Akt/FOXO3a Signaling Pathway. Med Sci Monit 23:5793–5802.
9. Wang J, Yan WX, Li JT, Peng SB, Li J, Xiao HJ, Wen XQ (2016)
Correlation between HDAC6 expression and clinical features of
renal cell carcinoma. Int J Clin Exp Pathol 9(9):9364–9371
10. Peters KB, Lipp ES, Miller E, Herndon JE 2nd, McSherry F,
Desjardins A, Reardon DA, Friedman HS (2018) Phase I/II trial
of vorinostat, bevacizumab, and daily temozolomide for recurrent
11. Moyal L, Goldfeiz N, Gorovitz B, Rephaeli A, Tal E, Tarasenko N,
Nudelman A, Ziv Y, Hodak E (2018) AN-7, a butyric acid prodrug,
sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via
inhibition of DNA double strand breaks repair. Investig New Drugs
12. Huang ZM, Peng SW, Knoff J, Lee SY, Yang B, Wu TC, Hung CF
(2015) Combination of proteasome and HDAC inhibitor enhances
HPV16 E7-specific CD8(+) T cell immune response and antitumor
effects in a preclinical cervical cancer model. J Biomed Sci 22.
13. Pont LM, Naipal K, Kloezeman JJ, Venkatesan S, van den Bent M,
van Gent DC, Dirven CM, Kanaar R, Lamfers ML, Leenstra S
(2015) DNA damage response and anti-apoptotic proteins predict
radiosensitization efficacy of HDAC inhibitors SAHA and
LBH589 in patient-derived glioblastoma cells. Cancer Letters 356
14. Qiu-He C, Rong-Biao P, Jing-Kao C (2016) Pharmacology of
Rhein and Advancement in the Synthesis of Its Derivatives.
15. Wu L, Cao K, Ni Z, Wang S, Li W, Liu X, Chen Z (2018) Rhein
reverses doxorubicin resistance in SMMC-7721 liver cancer cells
by inhibiting energy metabolism and inducing mitochondrial per-
meability transition pore opening. BioFactors (Oxford, England):8.
16. Zhang Q, Yin SS, Liu L, Liu ZH, Cao WS (2016) Rhein reversal of
DNA hypermethylation-associated Klotho suppression ameliorates
17. Liu S, Wang J, Shao T, Song P, Kong Q, Hua H, Luo T, Jiang Y
(2018) The natural agent rhein induces beta-catenin degradation
and tumour growth arrest. J Cell Mol Med 22(1):589–599. https://
29. Zhou WJ, Chen XX, He K, Xiao JF, Duan XP, Huang R, Xia ZL,
He JL, Zhang JQ, Xiang G (2016) Histone deacetylase inhibitor
screening identifies HC toxin as the most effective in intrahepatic
cholangiocarcinoma cells. Oncol Rep 35(5):2535–2542. https://doi.
30. Chen XC, Wei XT, Guan JH, Shu H, Chen D (2017) EGF stimu-
lates glioblastoma metastasis by induction of matrix
metalloproteinase-9 in an EGFR-dependent mechanism.